NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Allysta Pharmaceuticals

Allysta Pharmaceuticals

Private
Bellevue, WashingtonHealthcare & Life Scienceshttps://www.allysta.com/

Last Round

Series A

Dec 18, 2019

Total Funding Raised

$20.69M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Allysta Pharmaceuticals is a biopharmaceutical company that develops first-in-class therapeutic peptides for rare diseases with high unmet needs, such as Duchenne muscular dystrophy and dry eye disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B2C

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

Duchenne muscular dystrophytherapeutic peptidesDMDadiponectin receptor agonistrare disease treatmentorphan drugfirst-in-class drugclinical-stage biotechanti-fibrotic drugmuscle regenerationanti-inflammatory drugneuromuscular diseasesustained-release formulationpeptide drug discoverysubcutaneous injection

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Allysta Pharmaceuticals Comparables

Compare Allysta Pharmaceuticals with similar companies based on industry and business-model similarity.

Allysta Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Satellos Bioscience Inc.
76%
Capricor Therapeutics
74%
Dyne Therapeutics
71%
View all Comparables

Allysta Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 18, 2019
Convertible DebtApr 16, 2019
AcceleratorFeb 22, 2017
View all Funding Rounds

Key People

Founding team and executive leadership

Henry Hsu

CEO

Executive Team

Allysta Pharmaceuticals Investors

Notable investors and investment history

Allysta Pharmaceuticals investors
InvestorRounds
Morningside VenturesSeries A
QB3Accelerator
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors grew 47% MoM.

  • Nov 7, 2024

    Grew 700% QoQ, from 1 to 8 employees.

View all signals

Allysta Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Allysta Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Allysta Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersBellevue, Washington
Employee Range6
Year Founded2013
Last FundingDec 18, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.